Condition
Secondary Sclerosing Cholangitis
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Terminated1
Completed1
Unknown1
Active Not Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02545309Active Not RecruitingPrimary
Secondary Sclerosing Cholangitis in Critically Ill Patients
NCT05396755Not ApplicableTerminatedPrimary
Biliary Interventions in Critically Ill Patients With Secondary Sclerosing Cholangitis (BISCIT)
NCT05233553CompletedPrimary
SSC-COVID in Patients After COVID-19
NCT02701166Phase 3Unknown
The Effect of Bezafibrate on Cholestatic Itch
Showing all 4 trials